Dabur has moved quickly to take advantage of the ban.
'If someone were to ask you if you want to die tomorrow, no matter what problems you are grappling with, you would be hesitant, right?'
A day after the Supreme Court rapped the Health Ministry for allowing Indians to be used as 'guinea pigs' in the conduct of drug trials, top sources told PTI that the rules meant to monitor clinical trials under the Drugs and Cosmetics Act would be notified within this month.
.jpg)
The move is expected to delay the introduction of low-priced medicines in the market.
A regiment of 30,000 fighters for the Pakistan army in India depends largely on the money that is generated through skin trade and drug smuggling, a report of the military intelligence bureau has said. Vicky Nanjappa reports.
Over 20 drug companies marketing anti-obesity drug sibutramine under a variety of brand names are likely to soon face a ban on selling the medicine.
In another setback to Big Pharma, US drug major Eli Lilly's blockbuster erectile dysfunction drug Cialis (generic name:Tadalafil) has failed to qualify for a product patent in India after the basic constituent of the medicine was found to be a known substance, developed and patented by Indian scientists 32 years ago.
A notice issued by the Indian Health Ministry at the weekend said that a government-appointed committee of experts had found that the banned combinations were "likely to involve risk to human beings, whereas safer alternatives to the said drug are available."
Ranbaxy Laboratories has withdrawn all of its generic versions of antiretroviral drugs from World Health Organization's list of approved HIV medicines, saying it's uncertain they are biologically the same as the patented drugs.
FDA allows Teva to launch Nexium generic; Cipla, which supplies formulation, to gain
'People should know the names of all such drugs which have been banned.'
Roche said the Indian regulatory authorities had approved Biocon and Mylan's products as Trastuzumab, but it was unclear if these met the criteria for biosimilar products.
Industry is gathering scientific data to approach the regulator, DCGI, for a review of the suspension order.
The war of words between Arvind Kejriwal and Amarinder Singh turned ugly on Twitter on Monday after the Delhi Chief Minister accused the Punjab Congress chief of using an Akali leader's "drug money" to fund his election campaign and the latter shot back, saying the AAP leader was "hallucinating" and challenged him to a debate.
Earlier, Jaslok Hospital had issued an advisory to its doctors to avoid prescribing drugs manufactured by Ranbaxy.
Ranbaxy Laboratories Ltd said on Thursday that it has bagged the US Food and Drug Administration's approval for manufacturing and marketing Loratadine and Pseudoephedrine Sulfate Extended-release tablets.
The products worth Rs 5,000 crore have been banned for manufacture, distribution and sale with immediate effect causing hardship to manufacturers and patients.
The FDA has stepped up its efforts to ensure drug safety in recent months.
People die from diseases like AIDS, TB, etc because life saving essential medicines are either too expensive, or not available because they are not seen as financially viable.
Mandatory prescription of generic names is not a complete solution. Rather, in the absence of a range of approaches, it could mean passing the choice of selecting a drug from a doctor to a pharmacist, says Chandrakant Lahariya.
The idea is to keep a close watch on real-time price movements, the maximum retail price of medicines and their availability.
This is a good opportunity for long-term investors to pick quality small and midcap stocks at reasonable valuations.
After the first quarter was washed out, exporters are now keeping their fingers crossed over a turnaround in outbound shipments to at least North America from September onwards. This comes even as other key destinations such as Europe may take longer to revive in FY24. Slowdown in key economies, as well as geopolitical tensions resulted in sluggish demand for Indian goods.
The headline for corporate profit growth has been very encouraging in the July-September quarter (Q2) of 2023-24 (FY24), with the combined net profit of listed companies up by 38 per cent year-on-year. However, the earnings distribution has been very lopsided, with most of the growth coming from public-sector oil-marketing companies (OMCs), banks, non-bank lenders, automobile (auto) companies, and cement producers. By comparison, companies from information technology services, fast-moving consumer goods (FMCG), retail, and consumer durables were disappointed, experiencing a sharp slowdown in net sales growth and a relatively muted increase in reported net profit.
The Supreme Court on Tuesday said it was more interested in getting the black money stashed abroad back to the country than the disclosure of names of illegal account holders in foreign banks.
The Supreme Court on Thursday slammed the government again over the issue of illicit wealth parked in foreign banks, asking it to file a report on the action taken by it against people and firms that have stashed black money in tax havens abroad.
Keeping its word to make drugs affordable to consumers, the government on Thursday announced caps on margins on the sale of pharmaceutical products.
The National Pharmaceutical Pricing Authority (NPPA) on Thursday said it has increased prices of 62 drugs, which are mainly based on indigenously manufactured insulin, giving a filip to domestic firms.
Domestic drug major Cipla Ltd has signed a long-term collaboration agreement with Swiss specialty pharmaceutical major Meda, to develop and market an anti-allergic rhinitis drug for various global markets. Cipla will manufacture the drug, which will treat an ailment that causes a runny nose, and the Swiss company will market the product in Europe, Japan, Brazil, South Korea and Australia. The partners are developing the product as a nasal spray to treat allergic rhinitis.
Generic drugmakers cannot be sued under state law for adverse reactions to their products.
The government on Monday reduced basic customs duty on influenza vaccine and nine other specified life-saving drugs used for treating breast cancer, hepatitis-B, rheumatic arthritis, etc.
In a setback to former deputy chief minister Manish Sisodia, the Supreme Court on Monday denied him bail in the corruption and money laundering cases related to the alleged Delhi excise policy scam, saying the accusation of "windfall gains" of Rs 338 crore to wholesale liquor dealers was "tentatively supported" by evidence.
market, was today seized from an illegal drug manufacturing unit in Jalgaon district in north Maharashtra and six persons were arrested, Directorate of Revenue Intelligence officials said.
Sun Pharma could have to withdraw cancer drug as J&J re-enters after temporary eclipse
Former Narcotics Control Bureau (NCB) zonal director Sameer Wankhede is trying to show the alleged messages exchanged with film superstar Shah Rukh Khan as certificate of integrity, the Central Bureau of Investigation (CBI) told the Bombay high court on Monday during a hearing of a petition of the official who is accused of seeking Rs 25 crore as bribe from the actor for not implicating his son Aryan in the Cordelia cruise 'drug bust' case.
Wockhardt is recalling select drugs in the US, which were under import restrictions from the USFDA.
'We have often heard the mythical argument that patents block access to life-saving drugs, but only 5% of medicines from multinational companies are under patent protection in India.' 'Where these patented products are beyond the reach of Indian patients, the companies have programmes to facilitate access to their drugs, for free or for a fraction of the price,' points out Ranjana Smetacek, former director general, Organisation of Pharmaceutical Producers of India.
Ajit Mishra, vice president, Research, Religare Broking, answers your stock market queries.
Ranbaxy requested withdrawal of approval under a consent decree.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances